0000899243-21-048894.txt : 20211217 0000899243-21-048894.hdr.sgml : 20211217 20211217202733 ACCESSION NUMBER: 0000899243-21-048894 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211215 FILED AS OF DATE: 20211217 DATE AS OF CHANGE: 20211217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Renger John CENTRAL INDEX KEY: 0001830363 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 211503383 MAIL ADDRESS: STREET 1: C/O CEREVEL THERAPEUTICS, INC. STREET 2: 51 ASHTOR PLACE CITY: NEW YORK STATE: NY ZIP: 10003 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-15 0 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001830363 Renger John C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02421 0 1 0 0 Chief Scientific Officer Common Stock 2021-12-15 4 M 0 25000 3.50 A 26980 D Common Stock 2021-12-15 4 S 0 25000 30.0179 D 1980 D Common Stock 2021-12-16 4 M 0 5578 3.50 A 7558 D Common Stock 2021-12-16 4 S 0 5578 32.50 D 1980 D Common Stock 2021-12-17 4 M 0 7122 3.50 A 9102 D Common Stock 2021-12-17 4 S 0 7122 32.50 D 1980 D Stock Option (Right to Buy) 3.50 2021-12-15 4 M 0 25000 0.00 D 2029-04-02 Common Stock 25000 400875 D Stock Option (Right to Buy) 3.50 2021-12-16 4 M 0 5578 0.00 D 2029-04-02 Common Stock 5578 395297 D Stock Option (Right to Buy) 3.50 2017-12-17 4 M 0 7122 0.00 D 2029-04-02 Common Stock 7122 388175 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person. Includes 1,980 shares acquired under the Issuer's Employee Stock Purchase Plan on May 28, 2021. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. /s/ Mark Bodenrader, as Attorney-in-Fact 2021-12-17